Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab Adizutecan vs Standard of Care in ctDNA Positive Colorectal Cancer
NCT07023289Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2025
- Primary completion
- Nov 2029
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial in colorectal cancer (CRC) comparing Telisotuzumab Adizutecan Monotherapy with Standard of Care (SOC) (2 arms). Primary endpoint: Disease Free Survival at 51 months. Started Sep 2025; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07023289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07023289.